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Bone–cartilage crosstalk: a conversation for understanding
osteoarthritis
David M Findlay and Julia S Kuliwaba
Although cartilage degradation is the characteristic feature of osteoarthritis (OA), it is now recognized that
the whole joint is involved in the progression of OA. In particular, the interaction (crosstalk) between
cartilage and subchondral bone is thought to be a central feature of this process. The interface between
articular cartilage and bone of articulating long bones is a unique zone, which comprises articular cartilage,
below which is the calciﬁed cartilage sitting on and intercalated into the subchondral bone plate. Below the
subchondral plate is the trabecular bone at the end of the respective long bones. In OA, there are well-
described progressive destructive changes in the articular cartilage, which parallel characteristic changes in
the underlying bone. This review examines the evidence that biochemical and biomechanical signaling
between these tissue compartments is important in OA disease progression and asks whether such signaling
might provide possibilities for therapeutic intervention to halt or slow disease development.
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INTRODUCTION
Osteoarthritis (OA) manifests as degradation and loss of the
articular cartilage, but typically involves all tissues of the
joint. Although this review focusses on crosstalk between
the subchondral bone and articular cartilage in the
initiation and progression of OA, likely inputs from each
of the other tissues involved in the joint structure is
acknowledged.
Consideration of the crosstalk between bone and
cartilage as a factor in OA initiation and progression raises
several key questions. First, is it feasible that these tissue
compartments communicate? If so, is this communication
important in health and disease? Is the communication
biomechanical or biochemical, or both? Second, what are
the changes that take place in bone and cartilage during
the development of OA and how might these changes in
either tissue affect the other? Third, if there is a crosstalk
between bone and cartilage that is important in the
development of OA, could treatments for OA be directed
to modifying this crosstalk by inhibiting the disease-related
changes in these tissues? Should therapies be targeted to
bone or cartilage?
The evidence that will be reviewed below comes largely
from in vitro and animal experiments. For the most part, the
relevance of these data for human OA is not known, and
translation of treatments that has been effective in animals
has been disappointing in humans so far. Our under-
standing of human OA is enriched by population studies,
non-invasive imaging, and examination of joint tissues at
end-stage disease. It is hoped that higher-resolution
imaging studies, with a better appreciation of what these
mean at the tissue level, will drive this ﬁeld forward in terms
of developing new treatment strategies, and better
identiﬁcation of patients in whom these treatments might
be effectively applied.
FEASIBILITY OF BONE–CARTILAGE CROSSTALK
Although the articular cartilage overlies, and is in intimate
contact with the underlying subchondral bone, molecular
crosstalk between osteoblasts/osteocytes and chondro-
cytes in vivo, particularly in human joints, is unproven. The
traditional view has been that the calciﬁed layer of the
cartilage, immediately above the subchondral plate, and
the subchondral plate act as impenetrable barriers.
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However, there is a body of evidence suggesting that
these tissues can communicate. For example, the interface
between the subchondral bone and calciﬁed cartilage
contains numerous vascular canals.1 Duncan et al.2
described holes in the subchondral plate, which were
largely located beneath the area that is usually covered
by the meniscus, a consistent ﬁnding for healthy medial
tibial plateaus of knee joints. Some of these holes
appeared to penetrate the subchondral plate and con-
nect with the marrow space. These ﬁndings are consistent
with more recent descriptions of the human chondro-
osseous junction as being more complex than previously
appreciated, with uncalciﬁed cartilage frequently dipping
through the calciﬁed cartilage into bone and marrow
spaces,3 again suggesting a potential route for molecular
diffusion between the two compartments. Imhof et al.4
described the dense subchondral vasculature in close
proximity to the cartilage and the micro-channels that
penetrate the subchondral bone and permit communica-
tion between the bone and cartilage. These authors
claimed that 450% of the glucose, oxygen, and water
requirements of cartilage are provided by perfusion from
these subchondral vessels. Consistent with this, experimen-
tally induced hypoxia of the femoral head led to cell death
in both the bony epiphysis and in the deep layer of the
overlying cartilage.5 Work by Pan et al.,6 using ﬂuorescent
dyes, showed that small molecules (for example, sodium
ﬂuorescein, 376 Da) could diffuse readily between the
bone marrow and the articular space in mouse joints.
These observations show, at least in small mammals, the
possibility of direct signaling between the subchondral
bone and articular cartilage, at least for small molecules,
with the suggestion that cartilage and bone form a
functional unit, both mechanically and biochemically,
which may have a role in joint homeostasis and disease.
More relevant perhaps for larger mammals, including
humans, are experiments performed in healthy horse
metacarpal joints. Experiments in joints obtained immedi-
ately after death demonstrated that, in contrast to
previous reports, the tidemark and mineralized cartilage
are permeable to low-molecular-weight solutes.7 By perfus-
ing the joint ex vivo from the subchondral side with
ﬂuorescent dyes (~400 Da), it was observed that tracer
penetrated through the cartilage and after 1.5 h was
present in the synovial ﬂuid, suggesting that dye entry was
from the subchondral micro-circulation. These experiments
did not address the possibility of exchange of larger
molecules such as cytokines and to explore this further
the contribution of cyclic loading of the joint needs to be
considered. To do so, O’Hara et al.8 performed cyclic
loading of human femoral head articular cartilage and
found that it increased diffusion through the cartilage of
large molecules, such as human serum albumin (66.5 kDa),
but did not inﬂuence the diffusion of small solutes. More
recently, diffusion of insulin-like growth factor (7.6 kDa)
through the cartilage ex vivo was shown to be signiﬁcantly
enhanced by cyclic loading.9–10 Similarly, larger molecules
(12.3 kDa) than previously thought able to traverse osteo-
cyte canaliculi have been shown to do so and this
transport is increased by bone loading.11 Thus, there are
likely to be both vascular and other means, including via
the osteocyte lacuna–canalicular network of bone, for
signaling molecules to traverse between the bone and
cartilage.
In OA, there is increased ability for ﬂuid movement
between bone and cartilage, and therefore, presumably,
for trafﬁcking of humoral mediators. Hwang et al.12 found
that the hydraulic conductance (that is, the ease of ﬂuid
ﬂow) of human osteochondral plugs increased in associa-
tion with increasing cartilage erosion and subchondral
bone plate thickness and vascularity. The authors noted
that alteration of ﬂuid ﬂow across the cartilage–bone
interface could affect the mechanical and chemical
environment in ways that promote the progression of OA.
Several studies have suggested that there is increased
porosity of the subchondral plate in OA, which may
enhance the interaction between the bone and cartilage
compartments. A large increase in subchondral plate
porosity was shown during disease development in a
mouse model of instability-induced knee OA,13 and Iijima
et al.14 also found that subchondral plate porosity
increased during disease progression in a rat model of
post-traumatic knee OA. The increase in plate porosity and
consequent eruption of blood vessels through the plate
and into the calciﬁed cartilage seems to be due to the
increased osteoclastic activity.12–13 The molecular
mechanisms involved in the increased angiogenesis in
OA and the reduced ability of the cartilage to resist
vascular invasion have been well reviewed elsewhere.15 In
the Iijima study cited above,14 the increased porosity co-
localized with the point of mechanical load during
ambulation. We also found that bone marrow lesions in
the subchondral bone of human tibiae most frequently co-
located with predicted zones of maximal loading,16 and
that bone marrow lesions associate in turn with increased
porosity of the subchondral plate,16 and with microcrack
accumulation in the plate and calciﬁed cartilage (Kuli-
waba et al., unpublished). Bone marrow lesions are
discussed in more detail below, but it is relevant here to
cite reports that describe perfusion abnormalities in the
subchondral bone in both animal models of OA17–18 and
human OA, in particular in zones of the subchondral bone
identiﬁed as bone marrow lesions.19 If crosstalk between
the bone and cartilage is dependent on the diffusion of
factors from the subchondral vasculature, reduced perfu-
sion will have implications for this crosstalk.
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At the cell and tissue level
There is abundant evidence that cells in the bone,
particularly osteoblasts and osteocytes, and those in the
cartilage, chondrocytes, alter their behavior in OA. This
altered behavior, in particular for bone cells, is described in
more detail below. There are a range of environmental
cues that these changes in behavior could be in response
to, which include biomechanical and biochemical. It is
thought that overloading is an important driver of OA,
whether due to obesity or altered joint biomechanics, and
both chondrocytes20 and osteoblast/osteocytes21–22 have
well-developed mechano-sensing abilities. Other cues,
perhaps at different stages of the disease, include
damage to the matrix of the bone and cartilage, in which
these cells reside,23 perhaps also as a consequence of
inappropriate loading of the joint; hypoxia, perhaps due to
vascular pathology in the joint;24 and inﬂammation, which
when prolonged drives a catabolic agenda in the bone
and cartilage.25 It is also possible that cells in the bone and
cartilage compartments exert inﬂuence on each other
and there is in vitro and ex vivo evidence that they can do
this (described below). However, as discussed above,
although small molecules are able to traverse by diffusion
between the bone and cartilage, it is not clear whether this
applies to larger signaling molecules.
There is accumulating ex vivo and in vitro evidence that
events in the subchondral bone can affect the behavior of
the overlying cartilage. In an experiment with cultured
bovine osteochondral explants, Amin et al.26 reported that
articular cartilage in the absence of subchondral bone
showed increased chondrocyte death after 7 days, mainly
in the superﬁcial zone of the cartilage. In contrast, when
the subchondral bone was included in the culture, either
excised from the cartilage or remaining attached, the
chondrocytes remained largely viable. It was speculated
that soluble chondrocyte survival factor(s) were released
from the subchondral bone. Sanchez et al.27–28 have
described a co-culture system, in which osteoblasts
derived, respectively, from ‘sclerotic’ (more severely
osteoarthritic) or ‘non-sclerotic’ regions of the subchondral
bone in human patients with knee OA were separated by
a membrane from chondrocytes that were derived from
the articular knee cartilage and grown in alginate beads.
Compared with chondrocytes cultured alone, chondro-
cytes in the presence of ‘sclerotic’ osteoblasts, but not
‘non-sclerotic’ osteoblasts, showed reduced production of
the cartilage matrix protein aggrecan and increased
expression of the cartilage degrading enzyme, matrix
metalloproteinase (MMP)3 and MMP13. In more recent
experiments, these authors conﬁrmed reduced expression
of aggrecan messenger RNA (mRNA) by chondrocytes in
co-culture with ‘sclerotic’ osteoblasts.28 In addition, chon-
drocytes in these co-cultures showed reduced expression
of mRNA encoding collagen II α1 chains, and increased
gene expression of MMP3 and ADAMTS-4 and 5. These
effects of osteoblasts in co-culture were largely blocked by
neutralizing interleukin (IL)-6 antibodies. These results sug-
gest, ﬁrst, that osteoblasts obtained from the sclerotic
subchondral bone from OA patients somehow retain an
OA phenotype after removal from the body and expan-
sion, and culture ex vivo. Second, although it is not possible
to extrapolate from these in vitro ﬁndings to the in vivo
situation, nonetheless there is at least the possibility that
aberrant expression of molecules in OA by, in this case
osteoblasts, can affect chondrocyte behavior. Osteocytes
are the most abundant cell type in bone and are the
primary mechano-sensing cell type.29–30 The osteocyte
lacuna–canalicular network is in functional continuity with
the bone micro-vasculature.31 As discussed above, osteo-
cytes in the subchondral bone are closely juxtaposed to
the cartilage, and can potentially signal into the cartilage
via the lacuna–canalicular network or the bone micro-
vasculature. Very little has been reported concerning this
potential interaction; however, Priam et al.32 conducted
intriguing experiments with mouse calvarial osteoblasts/
osteocytes. The cells were subjected to cyclic compres-
sion, after which the conditioned medium was collected
and incubated with mouse articular chondrocytes. Condi-
tioned medium from the ‘loaded’ cells caused a marked
upregulation of MMP3 and MMP13 expression in the
chondrocytes and downregulation of the expression of
aggrecan and type II collagen. The study identiﬁed 14-3-3ε
as a soluble mediator for communication between the
osteoblasts/osteocytes and chondrocytes.32 This study
shows the possibility of mechanical inﬂuences in osteo-
blasts secondarily affecting articular chondrocytes, in
addition to direct responses by chondrocytes to load.20
Physiological loading is important for cartilage homeostasis
and can counter the catabolic effects of inﬂammatory
cytokines.33 However, overloading of joints is harmful and
persistent overloading is thought to be an important driver
of cartilage degradation. It has been speculated that
catabolic molecules from diseased cartilage can
adversely affect bone cells,34 but there are no direct data
to show that this occurs in situ.
Crosstalk in vivo
There are a number of in vivo experiments, which show the
inter-dependence of the subchondral bone and articular
cartilage compartments in OA induction and progression.
These experiments are of two types, namely, those that
induce OA by perturbing either the cartilage or bone,
but resulting in OA changes in the other compartment, and
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those where treatments of existing OA, which would be
expected to preferentially affect one compartment
(in most cases the bone), are protective of OA changes
in the other (usually the cartilage). An example of
experiments to perturb the cartilage is the injection of
vascular endothelial growth factor (VEGF) intra-articularly
into the knee joints of mice.35 The rationale for these
experiments was the consistent ﬁnding of increased VEGF
in the tissues of OA joints, including cartilage, subchondral
bone, and serum.36 In this model, exogenous VEGF initiated
a full range of osteoarthritic processes in the knee joint, with
a temporal sequence of synovial hyperplasia, tidemark
duplication in the calciﬁed cartilage and subchondral
bone sclerosis, followed by cartilage degradation.
The results suggested that perturbations on the articular
side of the joint, in this case with VEGF, resulted in changes
in all the tissues of the joint, including the subchondral
bone. However, it is not clear whether the observations
were direct, via signaling from VEGF-treated cartilage to
bone, or indirect, via circulating VEGF acting on bone. A
second example of intervening from the articular side
involves the Wnt inhibitor, Dkk-1.37 Members of the Wnt
family and their inhibitors are strongly associated with OA,
and Wnt signaling pathways have been suggested as
potential therapeutic targets.38 In this example, the mouse
OA model of destablization of the medial meniscus
was used to explore the effect of Dkk-1 overexpression
in the cartilage, either by adenoviral or transgenic
approaches. Although destablization of the medial
meniscus caused severe cartilage destruction, osteophyte
formation, and subchondral bone sclerosis in control
mice, these manifestations of OA were signiﬁcantly
inhibited by Dkk-1 overexpression in chondrocytes. These
results show that inhibition of the canonical Wnt
pathway by Dkk-1 speciﬁcally in articular chondrocytes is
sufﬁcient to prevent OA changes in the underlying bone
by joint destablization. The mechanism for this is not
yet known.
An example of perturbing the subchondral bone, with
protective effects for OA development in both bone and
cartilage, is a mouse model of osteoblast-speciﬁc
overexpression of the EphB4 receptor.39 The rationale for
these experiments was the growing understanding of the
role for the ephrin/Eph subfamily of membranous tyrosine
kinases in bone biology,40 prompting exploration of their
role in skeletal pathology. EphB4 transgenic mice were
resistant to OA development after destablization of the
medial meniscus surgery, compared with control mice. This
included the preservation of cartilage and subchondral
bone. These ﬁndings suggest that maintenance of the
metabolism and structure of the subchondral bone
following destablization of the joint by destablization of
the medial meniscus also protects the integrity of the
overlying cartilage. A second example is a mouse model
of bone-speciﬁc overexpression of TGFβ, which was found
to be causal of OA.41 The rationale for these experiments
was the strengthening case for a role for TGFβ in OA
pathogenesis, beginning with the increased amounts of
TGFβ protein measured in OA bone42 and synovial ﬂuid.43
In our own work, elevated levels of TGFβmRNA were found
consistently in bone from individuals with end-stage hip
OA,44 and cultured human osteoblasts isolated from
femoral bone of hip OA patients produced increased
TGFβ, which showed altered relationships with the expres-
sion of other cell regulatory molecules.45 The work by
Zhen et al.41 demonstrated in mice that high concentra-
tions of active TGFβ in the subchondral bone induce
abnormal bone formation and the degradation, and
loss of the overlying articular cartilage, resulting in OA.41,46
These authors produced transgenic mice expressing the
CED (Camurati–Engelmann)mutant form of TGFβ1, which is
released as active, rather than latent, TGFβ.47 Production of
the mutant protein speciﬁcally by osteoblastic cells led to
the activation of Smad2/3 (intracellular downstream TGFβ
signaling molecules) in the subchondral bone, but not in
the articular cartilage. The mutant mice showed
spontaneous OA-like changes in the subchondral bone
and degradation of the overlying cartilage.41 Evidence for
TGFβ acting in the subchondral bone being causal of OA
was shown in conventional mouse and rat OA models, in
which speciﬁc inhibition of TGFβ activity either in the
subchondral bone or systemically48–49 attenuated the
development of OA changes in both the subchondral
bone and articular cartilage. These results again show
that altered metabolism in the subchondral bone can
lead to all the manifestations of OA, including cartilage
degradation. As altered TGFβ signaling has subsequently
been shown in a spontaneous, age-related model
of OA, the Dunkin Hartley guinea pig,50 these latter
ﬁndings may have important implications for human
‘idiopathic’ OA.
Further evidence for the inter-dependence of bone and
cartilage comes from the results of experimental
treatments for OA. A number of attempts to modify OA
progression have focussed on the altered rate of bone
remodeling in the subchondral bone. As reviewed by Burr
and Gallant,51 this changes across the course of the
disease, with increased remodeling, accompanied with
increased vascularity, characteristic of early OA in animal
models of the disease, whereas late-stage disease is
characterized by the reduced bone resorption with a bias
towards bone formation. Increased bone remodeling, and
more speciﬁcally increased osteoclast numbers and
activity in the subchondral bone,52 has been identiﬁed as
a therapeutic target. The rationale for this is that the
resultant changes in bone structure and release of
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inﬂammatory cytokines produced by the resorptive
process may have biomechanical and biochemical
implications for the overlying cartilage. Thus, a number of
anti-resorptive agents have been investigated as
disease-modifying agents. Examples are alendronate in
rabbit models of OA,53–54 pamidronate in rat OA,55
calcitonin in dog OA,56 and osteoprotegerin in mouse
OA,57 each of which were shown to be chondroprotective.
It should be noted that, although the most obvious
interpretation for these agents offering cartilage protection
is that they do so secondary to inhibiting remodeling events
in the underlying bone, there may also be direct actions on
chondrocytes. Indeed, there is some evidence for direct
cell protective effects of bisphosphonates,58 calcitonin,59
and osteoprotegerin60 on chondrocytes.
Taken together, the evidence cited above shows the
close relationship that exists between the articular cartilage
and subchondral bone, which in at least some cases may
involve a crosstalk. The ﬁndings that treatments directed to
the subchondral bone are chondroprotective in animal
models has been exciting, but attempts to translate these
treatments to human OA have been largely disappointing.
It is likely that such studies have been confounded by all
the factors that make the existing animal models of OA
imperfect predictors of human disease. Human OA has a
long time course, is episodic, and frequently exists on a
background of ageing, obesity, metabolic disturbances,
joint malalignment, vitamin D deﬁciency, and declining sex
hormone status.61 In addition, although it is easy in animal
experiments to start therapy at the time of OA initiation, or
at a known time thereafter, this would only be possible in
post-traumatic OA in humans. Finally, genetic factors in
human populations are likely to hold considerable
inﬂuence, over which individuals progress to clinically
important joint disease, in both traumatic and
non-traumatic OA. Genetics determines bone shape,
cartilage thickness, and response of bone (and presum-
ably cartilage) to load.62 Importantly, as shown for inbred
strains of mice, there are strong genetic determinants of
articular cartilage repair following tissue injury to the joint.63
It is also interesting that in human patients undergoing
arthroscopic meniscectomy, a subset of patients showed
an articular cartilage gene expression pattern character-
istic of OA, despite their macroscopically normal
cartilage.64 Studies with larger cohorts will be required to
determine whether these gene expression patterns are
indeed predictive for OA. The study also showed associa-
tions between cartilage gene expression patterns and
age, body mass index, and sex. Such studies suggest ways
to understand the way that risk factors and genetic factors
work together to produce the manifestations of OA, and
will hopefully enable the targeting of treatments to
individuals most likely to respond.
CHANGES IN CELL BEHAVIOR IN OA COULD ALTER
BONE–CARTILAGE CROSSTALK
Associated with the initiation and progression of OA, a large
number of changes occur in the behavior of cartilage and
bone cells. This results in the altered expression of many
molecules, which could have both autocrine actions in
their tissue of production as well as contributing to an
altered conversation between the bone and cartilage
compartments, given that proteins and other larger
molecules are able to transit between these tissues.
There is an extensive literature describing the altered
expression proﬁle of chondrocytes in OA. A suite of
inﬂammatory cytokines,34 for example, TNFα and members
of the interleukin family, inﬂuence the function of chon-
drocytes away from normal homeostasis and anabolism
towards a catabolic phenotype. These cytokines arise both
externally, for example, from the synovium, or from the
traumatized chondrocytes themselves, and stimulate their
own expression in a positive-feedback loop, as well as
inducing chondrocytes to synthesize MMPs, proteases,
chemokines, nitric oxide, and eicosanoids such as prosta-
glandins and leukotrienes, all of which lead to increased
cartilage degradation (reviewed in Houard et al.65 and
Rahmati et al.66). Zhou et al.67 recently described the
molecular signature of human cartilage derived from
different regions of OA knees. They found much higher
expression of TNFα, IL-1β, IL-6, IL-11, and IFN-γ in cartilage of
OA grade 1–3 (macroscopic outerbridge grade), com-
pared with grade 0, and concomitant increases in
ADAMTS-5, MMP-8, and MMP-13, enzymes that degrade
the structure of articular cartilage by cleaving the aggre-
can and collagen II matrix scaffold. Interestingly, molecules
associated with osteoclasts were also elevated in grade
1–3 cartilage, including cathepsin K, TRAP, RANK, and
c-fms, as well as stimulators of osteoclast differentiation and
function, RANKL and M-CSF. RANKL expression has pre-
viously been shown to be elevated in elevated in
Osteoarthritis Research Society International (OARSI) grade
2 OA cartilage, predominantly in the pericellular regions of
the middle and deep zones of the cartilage.68 The authors
speculated that RANKL could diffuse from the deep
cartilage to contribute to changes in the subchondral
bone metabolism.
Evidence for a role for TGFβ in the bony changes of OA is
summarized above. TGFβ may also have a role in cartilage
in OA progression, although the data so far present a
confusing picture, as reviewed by Fang et al.69 It is reported
that TGFβ is present at low levels in mature cartilage, and
that its expression and signaling are upregulated in
OA. Further, the increased expression of TGFβ links with
induction of the matrix-degrading enzyme, HTRA1 in
chondrocytes.70 It is of interest that a phase II clinical trial
in a human OA cohort, in which allogeneic chondrocytes
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genetically engineered to overexpress TGFβ were injected
intra-articularly, reported positive preliminary results for pain
and function.71 Injury to cartilage also upregulates mem-
bers of the Wnt family. For example, WNT-16 was found to
be highly upregulated in the areas of cartilage damage72
and Wnt-3A induced the expression of MMP13 and
ADAMTS-4 in primary chondrocyte cultures.37 Interestingly,
the Wnt antagonists, sclerostin,73 and DKK-137 have been
shown to protect against cartilage destruction in vitro and
in vivo. Speciﬁcally, sclerostin protein was signiﬁcantly
increased in the focal areas of cartilage damage in
surgically induced OA in sheep and mice, as well as end-
stage human OA, and was shown to be biologically active
in chondrocytes. Exogenous sclerostin inhibited the Wnt-β–
catenin signaling and catabolic events in cartilage,
including IL-1α-stimulated cartilage aggrecanolysis in vitro.
A large number of proteins and genes show altered
expression in OA bone compared with that in bone from
control individuals without OA. In human OA, these studies
are limited to sampling at end-stage disease, from which it
is difﬁcult to interpolate to disease initiation and progres-
sion. Nevertheless, not only have clear differences been
found in OA bone compared with that from non-OA
individuals, but many of these differences are maintained
in cultured osteoblast-lineage cells derived from these
bone samples.74–75 Kuliwaba et al.76 measured RNA
extracted from the trabecular bone in the intertrochanteric
region of the proximal femur, and found reduced expres-
sion of IL-6, IL-11, and RANKL in OA bone compared with
age-matched autopsy controls. Interestingly, although
RANKL mRNA levels associated strongly with the structural
parameters Eroded Surface as a percent of Bone Surface
(ES/BS) and Osteoid Surface as a percent of Bone Surface
(OS/BS) in trabecular bone from control individuals, these
relationships were not apparent in OA bone,77 suggesting
that bone turnover is regulated differently in this disease.
Similar ﬁndings of reduced expression of RANKL mRNA in
OA bone were also reported when comparison was made
with bone from femoral neck fracture patients.78 Evidence
that bone formation is also altered in OA was that
osteocalcin mRNA expression was signiﬁcantly greater in
hip OA and, curiously, increased signiﬁcantly with age in
the OA group but not in controls.76 Kumarasinghe et al.79
found not only differences in gene expression between
femoral intertrochanteric OA and control bone but also
intriguing differences in the relationships between the
expression of individual genes and the relationships
between gene expression and structural indices (for
example, TWIST1 vs S100A4: r=+0.71, Po0.001, r=−0.30,
P=0.20 for OA and control, respectively; CTNNB1 vs OS/BS:
r=−0.07, P=0.77, r=+0.66, P=0.01 for OA and control,
respectively). Hopwood et al.44,80 performed gene micro-
array analysis on bone from the same region of the femur
and identiﬁed a large number of differentially expressed
genes in OA compared with control or osteoporotic bone.
A substantial number of the top-ranking differentially
expressed genes are known to have roles in bone
formation and, as reviewed by Kumarasinghe et al.,81
many of these genes are targets of either the Wnt or TGFβ/
BMP signaling pathways. These ﬁndings are consistent with
the roles for these signaling pathways already discussed
and with the increased amounts of insulin-like growth
factor types I and II, and TGFβ protein measured in OA in
bone from the iliac crest.42 This latter result, together with
the above ﬁndings in bone derived from the femoral
intertrochanteric region, and other related reports82 sug-
gest that bone metabolism may be disturbed throughout
the skeleton in OA, rather than these changes being
conﬁned to the subchondral bone. If this is the case,
several important questions arise: is altered bone metabo-
lism the cause or effect of OA; is it secondary to other
factors such as vitamin D deﬁciency or obesity?
To examine gene expression differences speciﬁcally in
the subchondral bone in OA, a number of groups have
performed gene microarray and PCR analysis in human
OA83 and animal models of OA.84–85 These studies are
difﬁcult to interpret but show the differential expression of
many genes associated with bone remodeling and
mineralization in human end-stage OA subchondral bone.
In the animal studies of surgically induced OA, more severe
OA manifestations were observed in older animals,
accompanied by many more differentially expressed
genes in the bone of older animals with OA.
ENHANCED CROSSTALK ASSOCIATED WITH BMLS
In human OA, the changes in bone and cartilage vary
considerably across the joint, typically beingmore severe in
the medial versus lateral knee joint. Altered remodeling
leads to altered bone structure, with increased Bone
Volume as a percent of Tissue Volume (BV/TV) in cancel-
lous bone and the formation of osteophytes.86–87 Increased
trabecular thickness, decreased trabecular spacing, and
reduced hardness of the bone in OA,88 due to decreased
mineral within the bone matrix,89 characterize the sub-
chondral bone, particularly in zones of the joint underlying
cartilage degeneration. The spatial association of these
changes strongly supports the notion of a close functional
relationship between subchondral bone and articular
cartilage. This relationship is further highlighted by examin-
ing bone marrow lesions (BMLs), discrete abnormalities that
can be visualized in the subchondral bone using magnetic
resonance imaging (MRI; reviewed in Bassiouni,90 and
Daheshia and Yao91). Although commonly observed in
symptomatic OA,92–95 BMLs are also seen in early (pre-
radiographic or asymptomatic) OA.96–98 There is growing
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evidence that BMLs can act as ‘reporters’ of OA, offering
prognostic and predictive value for disease progression,
and outcome measures for intervention strategies. Most
investigations of BMLs have been performed in knee OA,
where longitudinal studies have shown that their continued
presence is a potent risk factor for structural deter-
ioration, in particular the loss of cartilage volume and
quality.95,99–102 However, this was also a feature of BMLs in
the human femoral head.103 Thus, the presence of a BML
predicts future joint replacement.104
We have reported on a comprehensive characterization
of BMLs at the tissue level, where tibial plateaus were
obtained at knee arthroplasty for OA.16 BMLs were
identiﬁed in the subchondral bone ex vivo by performing
MRI at two clinically relevant sequences—T1- and PDFS-
weighted (T2) sequences. BMLs were detected in470% of
tibial plateaus, the remainder comprising a no-BML group
and two BML groups were recognized. In the ﬁrst group,
designated BML 1, BMLs were detected only by PDFS (59%
of BMLs); in the second group, designated BML 2, BMLs
were detected by both PDFS+T1 (41% of BMLs). The tissue
within an osteochondral unit deﬁned by a BML was
strikingly different from the surrounding tibial tissue. Most
importantly, BMLs were associated strongly with degenera-
tion of the overlying cartilage. When compared with no-
BML, TP with BML showed bone changes (Figure 1), which
included thicker subchondral plate (P=0.002), increased
trabecular bone volume and plate-like structures
(P=0.000 4), increased osteoid volume (P=0.002) and
thickness (P=0.005) and osteoid bridging and in-ﬁlling
(Figure 1), and a striking increase in microcrack density in
the subchondral trabeculae (P=0.000 1). OA bone
showed increased osteoclastic resorption (ES/BS) when
compared with the samples of control bone without OA
(P=0.005), although this parameter changed little across
no-BML-BML1, 2, within OA bone. We also found a higher
percentage of empty osteocyte lacunae in OA subchon-
dral trabecular bone compared with non-OA controls
(P=0.05), suggesting that the accumulation of micro-
damage may lead to a compromised osteocyte network
and subsequent osteocyte death, as reported in other
circumstances.23 BMLs also contained bone marrow
changes, which included more bone marrow edema
(P=0.03), ﬁbrosis (P=0.002), necrosis (P=0.01), small ﬁbro-
vascular cyst-like formations (P=0.04) (these were not seen
in control or no-BML bone), and the increased density of
Figure 1. Subchondral bone microarchitecture and osteoid seams characteristic of MRI identiﬁed bone marrow lesions (BMLs) in human tibial
plateaus obtained at knee arthroplasty surgery for OA. No signal was detected on PDFS and T1-weighted MRI sequences for no-BML. BML signal
was detected only by PDFS for BML 1; BML signal was detected by both PDFS and T1 for BML 2. Left panel shows three-dimensional reconstructed
micro-computed tomography (CT) images of a 10 mm diameter cylindrical region of interest within the volume of the BML. Left and right middle
panels show coronal and axial micro-CT images, respectively. Micro-CT images clearly demonstrate that BML subchondral bone is sclerotic,
characterized by thicker subchondral bone plate, and increased trabecular bone volume with more plate-like structure. Right panel shows von Kossa
silver/hematoxylin- and eosin-stained subchondral trabecular bone that shows BML tissue has increased osteoid, with increased osteoid seam
thickness, and osteoid bridging and in-ﬁlling. The sclerotic subchondral bone phenotype characteristic of BMLs was more pronounced for BML 2
versus BML 1.16
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thick-walled arterioles (P=0.002). Many of the changes
found in BMLs were reminiscent of those for the over-
expression of TGFβ in subchondral bone, for example,
increased osteoid and vasculature,41 suggesting the
possible involvement of TGFβ in human OA. In addition,
increased recruitment of mesenchymal stem cells was
recently described in regions deﬁned as BMLs of the
human femoral head,103 qualitatively similar to surgically
induced and TGFβ-induced OA in mice.41 Finally, BMLs in
our study were associated with changes in the overlying
cartilage, which included reduced cartilage volume
(P=0.008), tidemark duplication (P=0.01), increased vas-
cular cones penetrating into the cartilage (P=0.01), and
higher OARSI scores (P=0.004). For many measures, BML 1
was intermediate between no-BML and BML 2, prompting
the provisional conclusion that BMLs detected by speciﬁc
MRI sequences identify different degrees of degeneration
in the osteochondral unit.16 This conclusion is supported by
a separate study in 297 adults without incident knee pain,
in which BMLs present on both T1- and T2 (PDFS)-weighted
MRI sequences were associated with signiﬁcantly
increased medial tibial cartilage loss and incident knee
pain after 2 years, compared with those BMLs seen only on
T2-weighted sequences.105 Taken together, this work
suggests, ﬁrst, that MRI imaging of BMLs may enable the
identiﬁcation of different OA phenotypes and more
targeted treatments in OA. Second, there was a clear
relationship between the presence of a BML in the
subchondral bone and cartilage abnormalities. However,
because all sampling was at end-stage disease, it was not
possible to determine whether changes in one tissue
compartment caused changes in the other or whether
both bone and cartilage were responding independently
to the same tissue insult. It is instructive in this context to
note the results of a study, in which a single session of cyclic
compressive loading was applied across the knee joint of
mice. This led to rapid morphological and cellular altera-
tions in both the subchondral bone and articular cartilage,
the latter being persistent.106
SUMMARY AND CONCLUSIONS
The major points of the review are summarized in Figure 2,
including the putative role of crosstalk between subchon-
dral bone and cartilage, as both a means of maintaining
the health of the joint and a disease mechanism in OA. The
physiological load chronic over-load
BML











HEALTHY JOINT OA JOINT
Figure 2. Cartoon of healthy and OA knee joints. Shown is a healthy joint, in which physiological loading (magnitude of load× frequency of
loading) is managed by the joint. Healthy subchondral blood vessels and blood perfusion, and a putative healthy crosstalk between the subchondral
bone and articular cartilage lead to coupled bone remodeling to maintain homeostasis and repair microdamage in the bone matrix. In the OA joint,
chronic overloading results in failed repair mechanisms. Bone within a bone marrow lesion (BML) zone, imaged by MRI, contains the most severe
bony manifestations, in which dysregulated bone remodeling results in both bone attrition and sclerosis. The cartilage overlying the BML is
degraded, with increased matrix proteases and decreased production of cartilage matrix. A putative unhealthy crosstalk between the bone and
cartilage compartments exacerbates the failure of repair mechanisms, in the face of continued unfavourable biomechanics.
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studies summarized above show the feasibility of such
crosstalk. However, with respect to a role for this crosstalk in
the development of human OA, many questions remain.
Do signaling molecules from bone and cartilage traverse
between these tissue compartments? If so, is this a cause or
a result of OA? Are the reported animal and in vitro studies
informative of human OA? How can we obtain better data
for human OA earlier in the disease process? Are
molecules such as VEGF and TGFβ, which appear to be
key drivers of mouse OA by acting in one or both
compartments, also central players in human OA? If so,
how can this knowledge be exploited to treat human OA
and how could responsive subjects be identiﬁed? There is a
clear need for longitudinal studies in human OA, using
high-resolutionmodalities such as MRI, to better understand
this disease and that will enable stratiﬁcation of human
subjects into those who are likely to progress, or heal, or be
responsive to treatment. The above data allow cautious
optimism that we are approaching this point in the history
of OA research.
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